An assessment of thimerosal use in childhood vaccines.
Level 5 - mechanism / opinion, no new human data
Narrative review and regulatory risk assessment relying on mechanism-based reasoning and toxicological modeling without original clinical data.
PubMed 11331700 · doi:10.1542/peds.107.5.1147
What was done
The FDA conducted a risk assessment comprising hazard identification, dose-response assessment, exposure assessment, and risk characterization. The literature on the toxicity of thimerosal, ethylmercury, and methylmercury was reviewed. Maximal potential mercury exposure from vaccines was calculated for children at 6 months and 2 years of age under the US childhood immunization schedule and compared with safety thresholds from the EPA, ATSDR, FDA, and WHO.
What was found
The abstract reports no specific numerical exposure values or threshold quantities. The authors found that high-dose inadvertent exposure leads to neurotoxicity and nephrotoxicity, along with recognized delayed-type hypersensitivity. Cumulative mercury exposure from thimerosal during the first 6 months of life was calculated to potentially exceed EPA guidelines depending on immunization schedule, formulation, and infant weight. The review revealed no evidence of harm caused by vaccine-level thimerosal doses, except for local hypersensitivity reactions.
Why it matters
This regulatory assessment served as the primary rationale for the US public health recommendation to remove thimerosal from infant vaccines as a precautionary measure.
Limits
The conclusions depend on exposure modeling and extrapolation from methylmercury due to limited low-dose ethylmercury data. The abstract presents no original empirical clinical data and omits exact numerical exposure figures.
Cited by
- partial Cumulative mercury exposure from childhood vaccines in infants prior to the 2000 phase-out exceeded the EPA safe exposure limit by approximately 162 times.
- supports Around the year 2000, thimerosal was removed from most childhood vaccines in the United States, remaining primarily in multi-dose influenza vaccines and select others.